House Dems Hunt Pharma Big Game, Shutdown Ripples, & JPM Reflections

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

The PCSK9 Price Cut, J&J Depression Drug Passes Test, & Gilead’s NASH Strikeout
Azar Angles for a Deal Pharma Can Live With, Macrogenics’ Big Break, & Sanofi Scraps 38 R&D Programs
Genentech CEO in, Editas CEO Out, & the Shutdown IPO?
Lilly Buys Loxo, Baselga Resurfaces, and Bluebird’s Gene Therapy Payment Plan